BioSystem Development

By Adam Bonislawski
Agilent Technologies and Integrated Diagnostics said this week that they have entered a strategic partnership to develop mass spec workflows for protein biomarker diagnostics.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has completed the acquisition of BioSystem Development for an undisclosed sum.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Agilent Technologies today announced two deals that are expected to grow its footprint in the life science space.

The firm, which makes the AssayMap platform, plans to use the funds to scale up its manufacturing capabilities, increase the speed to market of its new products, and support expansion of its product pipeline.

Agilent will integrate mass-tagged PCR primers with LC-MS to enable the rapid identification of food-borne pathogens in one deal with UC-Davis, and combine its automated liquid handling platform with BioSystem's AssayMap high-throughput micro-chromatography technology in another collaboration.

The firms are combining their respective technologies to provide a platform that they said could process hundreds of samples in three hours or less.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.